Dissecting Pivotal Research in Lower-Risk MDS, From ASCO 2025 - Episode 3

How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.

EP. 1: Recent Shifts in the Management of Lower-Risk MDS
EP. 2: OS Data From COMMANDS for Luspatercept in ESA-Naive, Lower-Risk MDS
Now Viewing
EP. 3: How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS
EP. 4: Integrating Luspatercept Into Clinical Practice and Community Settings in ESA-Naive Lower-Risk MDS
EP. 5: Navigating Second-Line Treatment Decisions in Lower-Risk MDS
EP. 6: Key Areas of Ongoing Research in MDS

Related Content:

The University of Texas MD Anderson Cancer CenterDissecting Pivotal Research in Lower-Risk MDS, From ASCO 2025OncLive News Network®Myeloproliferative Neoplasms
Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis
INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis
Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML